Carla specialises in molecular biology, biotechnology, biochemistry and pharmaceuticals, with particular expertise in protein therapeutics and second medical uses. Much of her successful practice is dedicated to handling European Patent Office (EPO) opposition proceedings. She has extensive experience in attack and defence both at first instance and appeal and she has been involved in many multiparty disputes. Her experience in antibody-related opposition cases inter alia concerns numerous blockbuster products (such as rituximab, trastuzumab, pertuzumab and adalimumab), epitope related claims, bispecific antibodies, antibody glycosylation as well as recombinant expression technologies and purification methods.
Further core aspects of her practice include patent drafting and prosecution, freedom to operate analyses and national patent litigation and nullity proceedings.
Carla studied biology at the University of Cologne majoring in molecular biology, biochemistry, organic chemistry and pharmacology. She began her intellectual property career in 2000 in internationally active patent law firms and became a partner at KSVR in 2006.